Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas, Pfizer Extend Lipitor Licensing Term
March 30, 2012
- Daiichi Sankyo Enters Research Collaboration Agreement on Diabetes Therapy with US Venture Company
March 30, 2012
- Otsuka Chemical to Split Up Glycotechnology Laboratory to Make It New Company
March 30, 2012
- More Than 70% of Doctors Say “Frequency of Meetings Will Not Change” Despite Review of Entertainment: CareNet Survey
March 29, 2012
- Takeda’s Novel Renal Anemia Drug Omontys Approved in the US
March 29, 2012
- Astellas Files MAA for Fixed-Dose Combination of Vesicare/Harnal in Europe
March 29, 2012
- Fujifilm, Kyowa Hakko Kirin Establish JV to Develop Biosimilars
March 29, 2012
- No Change in Wholesalers’ Business Entertaining Rules for Time Being; Status of MSs with MR Qualification Remains Unclear
March 29, 2012
- Astellas to Place Greater Importance on China Business: Executive Katayanagi
March 28, 2012
- Nippon Shinyaku Submits NDA for Alcohol Abstinence Aid Acamprosate
March 28, 2012
- Ajinomoto, Takeda Submit Domestic Application for Once-Monthly Risedronate
March 28, 2012
- Anticancer Agents Set to Become Top Therapeutic Category in 2012: IMS Japan
March 28, 2012
- Nichi-Iko Provides Wholesalers with Monthly Supply Volume of Epadel Generic
March 27, 2012
- Epadel Generic in Short Supply at Sawai Pharmaceutical Due to Promotional Measures
March 26, 2012
- Daiichi Sankyo Submits NDA for Denosumab for Osteoporosis in Japan
March 26, 2012
- Daiichi Sankyo to Develop Unapproved Narcotic Analgesic in Japan
March 26, 2012
- Suzuken Establishes New Company Specializing in Rare Diseases
March 26, 2012
- Nexium No. 1 in MR Call Frequency in HP Market in February: Rep Track Survey
March 26, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 3
March 26, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 4
March 26, 2012
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…